Discovery of a Human Neuromedin U Receptor 1-Selective Hexapeptide Agonist with Enhanced Serum Stability.

Neuromedin U (NMU) activates two NMU receptors (NMUR1 and NMUR2) and is a useful antiobesity drug lead. We report discovery of a hexapeptide agonist, 2-thienylacetyl-Trp1-Phe(4-F)2-Arg3-Pro4-Arg5-Asn6-NH2 (4). However, the NMUR1 selectivity and serum stability of this agonist were unsatisfactory. Through a structure-activity relationship study focused on residue 2 of agonist 4, serum stability, and pharmacokinetic properties, we report here the discovery of a novel NMUR1 selective hexapeptide agonist 7b that suppresses body weight gain in mice.

Neuroendocrine regulatory peptide-1 and -2 (NERPs) inhibit the excitability of magnocellular neurosecretory cells in the hypothalamus.

Neuroendocrine regulatory peptide (NERP)-1 and NERP-2 (NERPs) are novel carboxy-terminally amidated peptides derived from the neurosecretory protein VGF. NERPs are colocalized with vasopressin in the paraventricular nucleus (PVN) and the supraoptic nucleus (SON) of the hypothalamus, and suppress vasopressin secretion evoked by intracerebroventricular administration of angiotensin II (AngII) and hypertonic saline or bath administration of AngII. Magnocellular neurosecretory cells (MCNs) of the hypothalamus release vasopressin and oxytocin from their dendrites and soma. The two cell types have common electrophysiological properties in response to glutamate and AngII. We investigated the mechanisms underlying the suppressive effects of NERPs on MCNs. Microdialysis of the PVN demonstrated that NERPs suppressed glutamate release induced by AngII. A whole-cell patch-clamp study of the SON showed that NERPs suppressed the potentiation of excitatory postsynaptic currents (EPSCs) evoked by AngII without affecting the amplitude, indicating that NERPs suppressed EPSCs by a presynaptic mechanism. The suppressive effect of NERP-2, but not NERP-1, was blunted in the presence of tetrodotoxin and bicuculline, a γ-aminobutyric acid (GABA) A receptor antagonist. These results indicate that NERP-1 suppresses presynaptic glutamatergic neurons connected to MNCs, whereas NERP-2 activates GABAergic interneurons, which suppress presynaptic glutamatergic neurons; thus, both peptides suppress vasopressin release. This study demonstrates that NERPs function as inhibitory modulators of vasopressin release.

Continuous stress promotes expression of VGF in melanotroph via suppression of dopamine.

Prolonged exposure to stress elicits profound effects on homeostasis that may lead to cryptogenic disorders such as chronic fatigue syndrome. To investigate the pathophysiology associated with the syndrome, we used a rat continuous stress (CS) model where the pituitary represents one of the most affected organs. Here we found that mRNA for VGF (non-acronymic), a member of the granin family, was induced specifically in the intermediate lobe (IL). This was matched by a concomitant increase at the peptide/protein level assessed by C-terminal antibody. Furthermore, the up-regulation of VGF was confirmed by immunohistochemistry in a subset of melanotrophs. VGF expression was altered in the IL of rats receivingthe dopamine D2 receptor agonist bromocriptine or the antagonist sulpiride. In vitro, dopamine dose-dependently decreased the mRNA levels in cultured melanotrophs. These findings suggest that VGF expression under CS is negatively regulated by dopaminergic neurons projecting from the hypothalamus.

Identification and biological activity of ovine and caprine calcitonin receptor-stimulating peptides 1 and 2.

We have recently reported the isolation of three new members of the calcitonin (CT) gene-related peptide family of peptides, the CT receptor (CT-R)-stimulating peptides (CRSPs). We now report the sequencing and characterization of ovine/caprine CRSP-1 and caprine CRSP-2. Mature ovine and caprine CRSP-1 are identical and have strong structural homology to CRSP-1s identified to date from other species. As with other CRSP-1s, ovine/caprine CRSP-1 binds to and activates the CT-R but not the CT-like receptor (CL-R) in combination with the receptor activity-modifying proteins (RAMPs). By contrast, caprine CRSP-2 does not activate any of these receptor-RAMP complexes. Intravenous infusions of ovine CRSP-1 to normal conscious sheep induced dose-dependent reduction in plasma total Ca levels (P=0.02) and corrected Ca levels (P=0.017) associated with increases in plasma cAMP (P=0.002). CRSP-1 reduced both plasma amino-terminal pro-C-type natriuretic peptide levels (P=0.006) and plasma renin activity (P=0.028). There were no significant effects observed on hemodynamic or renal indices measured. In conclusion, we have sequenced ovine/caprine CRSP-1 and caprine CRSP-2 precursors. This newly identified CRSP-1 has been shown to share the structural and biological features of CRSP-1s known to date. In vivo studies confirm that ovine CRSP-1 reduces plasma Ca levels in sheep, presumably via a cAMP-mediated mechanism. By contrast, caprine CRSP-2 did not stimulate any combination of CT-R, CL-R, and RAMPs. Accession numbers of cDNA determined in this study are caprine CRSP-1, AB364646; caprine CRSP-2, AB364647; and ovine CRSP-1, AB364648.